Open AccessA paired-agent fluorescent molecular imaging strategy for quantifying antibody drug target engagement in in vivo window chamber xenograft models
Author(s) -
Elif Kayaalp-Nalbant,
Cody Rounds,
Negar Sadeghipour,
Boyu Meng,
Margaret R. Folaron,
Chandrika Haldar,
Rendall R. Strawbridge,
Kimberley S. Samkoe,
Scott C. Davis,
Kenneth M. Tichauer
Publication year - 2020
Publication title -
pubmed central
Language(s) - English
Resource type - Conference proceedings
SCImago Journal Rank - 0.192
H-Index - 176
pISSN - 0277-786X
DOI - 10.1117/12.2545182
Subject(s) - in vivo , fluorescence , antibody , molecular imaging , drug , fluorescence lifetime imaging microscopy , preclinical imaging , biophysics , chemistry , biomedical engineering , medicine , pharmacology , biology , immunology , physics , microbiology and biotechnology , quantum mechanics
A paired-agent fluorescent molecular imaging strategy is presented as a method to measure drug target engagement in whole tumor imaging. The protocol involves dynamic imaging of a pair of targeted and control imaging agents prior to and following antibody therapy. Simulations demonstrated that antibody "drug target engagement" can be estimated within a 15%-error over a wide range of tumor physiology (blood flow, vascular permeability, target density) and antibody characteristics (affinity, binding rates). Experimental results demonstrated the first in vivo detection of binding site barrier, highlighting the potential for this methodology to provide novel insights in drug distribution/binding imaging.